<?xml version="1.0" encoding="UTF-8"?>
<ref id="ajh25238-bib-0003">
 <label>3</label>
 <mixed-citation publication-type="journal" id="ajh25238-cit-0003">
  <string-name>
   <surname>Lancet</surname>
   <given-names>JE</given-names>
  </string-name>, 
  <string-name>
   <surname>Cortes</surname>
   <given-names>JE</given-names>
  </string-name>, 
  <string-name>
   <surname>Hogge</surname>
   <given-names>DE</given-names>
  </string-name>, et al. 
  <article-title>Phase 2 trial of CPX‐351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML</article-title>. 
  <source xml:lang="en">Blood.</source>
  <year>2014</year>;
  <volume>123</volume>:
  <fpage>3239</fpage>‐
  <lpage>3246</lpage>.
  <pub-id pub-id-type="pmid">24687088</pub-id>
 </mixed-citation>
</ref>
